PMID- 31705978
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20200424
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 572
DP  - 2019 Dec 15
TI  - Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug 
      targeting.
PG  - 118716
LID - S0378-5173(19)30761-6 [pii]
LID - 10.1016/j.ijpharm.2019.118716 [doi]
AB  - There are various drug delivery systems (DDSs) among which nanoliposomal 
      formulations are among the most prominent. Despite the superiority of 
      nanoliposomal DDSs compared to conventional drug delivery methods, recent reports 
      have claimed that they can deliver small amounts of the injected dose to target 
      site by passive targeting. However, our understanding of tumor microenvironment 
      features, including dysregulation of pH, the high intracellular concentration of 
      glutathione, change in the amount and expression of some enzymes, reactive oxygen 
      species, hypoxia, and ATP concentrations, has driven the scope of research into 
      the use of these endogenous stimuli for a design of smart linkers. These linkers 
      optimize the release of payloads in favorable target sites and avoid premature 
      releasing in non-favorable off-target sites. In this review, we discuss 
      particular linkers, which are able to respond to the specific endogenous 
      conditions, and could be used in nanoliposomal DDSs, based on pathophysiological 
      changes that occur in tumors. Furthermore, structural and chemical properties of 
      these linkers and other potential linkers, which could be used in nanoliposomal 
      DDSs, have been reviewed.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Faal Maleki, Mahdi
AU  - Faal Maleki M
AD  - Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Jafari, Arash
AU  - Jafari A
AD  - School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
FAU - Mirhadi, Elaheh
AU  - Mirhadi E
AD  - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical 
      Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Askarizadeh, Anis
AU  - Askarizadeh A
AD  - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical 
      Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Golichenari, Behrouz
AU  - Golichenari B
AD  - Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
FAU - Hadizadeh, Farzin
AU  - Hadizadeh F
AD  - Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of 
      Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical 
      Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Jalilzadeh Moghimi, Seyed Mohammad
AU  - Jalilzadeh Moghimi SM
AD  - Sobhan Oncology CO., No. 11, 5th alley, Bucharest Ave., Argentina Sq., Tehran, 
      Iran.
FAU - Aryan, Reihaneh
AU  - Aryan R
AD  - School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Mashreghi, Mohammad
AU  - Mashreghi M
AD  - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical 
      Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, 
      Mashhad, Iran. Electronic address: mashreghim931@mums.ac.ir.
FAU - Jaafari, Mahmoud Reza
AU  - Jaafari MR
AD  - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical 
      Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, 
      Mashhad, Iran. Electronic address: Jafarimr@mums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191106
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Liposomes)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/chemistry
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Liposomes
MH  - Nanoparticles/*administration & dosage/chemistry
MH  - Neoplasms/*drug therapy
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Chemical linker
OT  - Condition dependent linker
OT  - Nanoliposome
OT  - Stimuli-responsive
OT  - Tumor microenvironment
EDAT- 2019/11/11 06:00
MHDA- 2020/04/25 06:00
CRDT- 2019/11/10 06:00
PHST- 2019/07/14 00:00 [received]
PHST- 2019/09/17 00:00 [revised]
PHST- 2019/09/18 00:00 [accepted]
PHST- 2019/11/11 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2019/11/10 06:00 [entrez]
AID - S0378-5173(19)30761-6 [pii]
AID - 10.1016/j.ijpharm.2019.118716 [doi]
PST - ppublish
SO  - Int J Pharm. 2019 Dec 15;572:118716. doi: 10.1016/j.ijpharm.2019.118716. Epub 
      2019 Nov 6.